Previous Close | 26.82 |
1-Year Change | 25.21% |
6-Months Change | 13.12% |
3-Months Change | 23.42% |
Moving Avg (50d) | 24.957 |
Moving Avg (200d) | 22.977 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 8.34B |
Beta (3-Years) | 0.61 |
Revenue Growth (ttm) | 8.31% |
Net Profit Margin (ttm) | 5.19% |
Return On Assets (ttm) | 3.09% |
EPS (ttm) | 0.28 |
PE Ratio (ttm) | 95.79 |
Dividend Yield | % |
Asset Description: | Exelixis, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2024-08-07 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
26.284 | 25.479 | 24.943 | 24.138 | 22.797 | 21.456 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia